14

In recent months, we have been witnessing a revolution in the field of inflammatory bowel disease (IBD). The rapid expansion of our therapeutic arsenal—as evidenced by the recent arrival on the market of Janus kinase inhibitors (JAKis), anti-IL23 agents, and sphingosine 1-phosphate modulators, along with their reimbursement in France—offers genuine promise for the management of our patients.This revolution is unfolding alongside a major global epidemic of Crohn’s disease and ulcerative colitis. For a long time, these conditions were regarded as “diseases of the young.” However, the global increase in incident IBD cases has revealed a growing number of presentations with either pediatric-onset or, conversely, geriatric-onset forms, each carrying their own medical, social, and environmental specificities.At a time when we are broadening our treatment perspectives and setting increasingly ambitious therapeutic goals, we often find that these “medical” objectives clash with those of our patients. Management must therefore be adjusted to take into account not only the patient’s profile (age, mobility, schooling, comorbidities, life projects, etc.) but also the characteristics of our therapies (e.g., safety, tolerance, administration mode, possibility for reimbursement). All these factors represent a real challenge for the practitioner and make the management of IBD patients increasingly complex. Here, we offer an overview of the latest news in IBD, addressing the various themes necessary to ensure a holistic approach to patient care.